Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)

New England Journal of Medicine

Volumn 342, Issue 23, 2000, Pages 1686-1692

  Nortier, Joëlle L ^a   Martinez, Marie Carmen Muniz ^a   Schmeiser, Heinz H ^b   Arlt, Volker M ^b   Bieler, Christian A ^b   Petein, Michel ^a   Depierreux, Michel F ^a   De Pauw, Luc ^a   Abramowicz, Daniel ^a   Vereerstraeten, Pierre ^a   Vanherweghem, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID;

ARTICLE; CANCER RISK; CARCINOGENICITY; CHINESE HERB; DOSE RESPONSE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; UROGENITAL TRACT CANCER; UROTHELIUM;

ANTI-OBESITY AGENTS; ARISTOLOCHIC ACIDS; CARCINOGENS; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OCHRATOXINS; PHENANTHRENES; PREVALENCE; RISK FACTORS; URETER; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 0034622082     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200006083422301     Document Type: Article

References (39)

1. Vanherweghem J-L, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91.
2. Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem J-L. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 1994;24:172-80.
3. Cosyns J-P, Jadoul M, Squifflet J-P, et al. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 1994;45:1680-8.
4. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem J-L. Identification of aristolochic acid in Chinese herbs. Lancet 1994;343:174.
5. Mengs U, Lang W, Poch J-A. The carcinogenic action of aristolochic acid in rats. Arch Toxicol 1982;51:107-19.
6. Schmeiser HH, Pool BL, Wiessler M. Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 1986; 7:59-63.
7. Pezzuto JM, Swanson SM, Mar W, Che C, Cordell GA, Fong HHS. Evaluation of the mutagenic and cytostatic potential of aristolochic acid (3,4-methylenedioxy-8-methoxy-10-nitrophenanthrene-1-carboxylic acid) and several of its derivatives. Mutat Res 1988;206:447-54.
8. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns J-P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996;56: 2025-8.
9. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 1997;18:1063-7.
10. Cosyns J-P, Jadoul M, Squifflet J-P, Van Cangh P-J, van Ypersele de Strihou C. Urothelial malignancy in nephropathy due to Chinese herbs. Lancet 1994;344:188.
11. Vanherweghem J-L, Tielemans C, Simon J, Depierreux M. Chinese herbs nephropathy and renal pelvic carcinoma. Nephrol Dial Transplant 1995;10:270-3.
12. Nortier J, Simon J, Petein M, et al. Chinese herbs nephropathy and urinary tract carcinoma. J Am Soc Nephrol 1998;9:164A. abstract.
13. Cosyns J-P, Jadoul M, Squifflet J-P, Wese F-X, van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999; 33:1011-7.
14. Angell M, Kassirer JP. Alternative medicine - the risks of untested and unregulated remedies. N Engl J Med 1998;339:839-41.
15. Cabanne F, Pagès A, Billerey C, Oppermann A, Carbillet J-P, eds. Pathologie génitale masculine: uropathologie. Paris: Masson, 1992:354-5.
16. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss, 1997.
17. Bostwick DG, Eble JN, eds. Urologic surgical pathology. St. Louis: Mosby-Year Book, 1997:246-7.
18. Murphy WM, Soloway MS. Urothelial dysplasia. J Urol 1982;127: 849-54.
19. Richards B, Parmar MKB, Anderson CK, et al. Interpretation of biopsies of "normal" urothelium in patients with superficial bladder cancer. Br J Urol 1991;67:369-75.
20. Pfohl-Leszkowicz A, Grosse Y, Castegnaro M, et al. Ochratoxin A-related DNA adducts in urinary tract tumours of Bulgarian subjects. In: Phillips DH, Castegnaro M, Bartsch H, eds. Postlabelling methods for detection of DNA adducts. Lyon, France: International Agency for Research on Cancer, 1993:141-8. (IARC scientific publications no. 124.)
21. Everson RB, Randerath E, Santella RM, Cefalo RC, Avitts TA, Randerath K. Detection of smoking-related covalent DNA adducts in human placenta. Science 1986;231:54-7.
22. Castegnaro M, Mohr U, Pfohl-Leszkowicz A, et al. Sex-and strain-specific induction of renal tumors by ochratoxin A in rats correlates with DNA adduction. Int J Cancer 1998;77:70-5.
23. McIntyre M. Chinese herbs: risk, side effects, and poisoning: the case for objective reporting and analysis reveals serious misrepresentation. J Altern Complement Med 1998;4:15-6.
24. Malak J. Chinese herb nephropathy is not a (dex)fenfluramine nephropathy but a serotonin nephropathy. J Altern Complement Med 1998; 4:131-5.
25. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998;338:446-52.
26. Kliem V, Thon W, Krautzig S, et al. High mortality from urothelial carcinoma despite regular tumor screening in patients with analgesic nephropathy after renal transplantation. Transpl Int 1996;9:231-5.
27. Stefanović V, Polenaković MH. Balkan nephropathy: kidney disease beyond the Balkans? Am J Nephrol 1991;11:1-11.
28. Ochratoxin A. In: IARC monographs on the evaluation of carcinogenic risks of chemicals to humans. Vol. 56. Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. Lyon, France: International Agency for Research on Cancer, 1993:489-521.
29. De Broe ME. On a nephrotoxic and carcinogenic slimming regimen. Am J Kidney Dis 1999;33:1171-3.
30. Mengs U, Stotzem CD. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch Toxicol 1993; 67:307-11.
31. Jackson L, Kofman S, Weiss A, Brodovsky H. Aristolochic acid (NSC-50413): phase I clinical study. Cancer Chemother Rep 1964;42:35-7.
32. Schmeiser HH, Pool BL, Wiessler M. Mutagenicity and in vitro metabolism of aristolochic acid. Biochem Pharmacol 1985;34:455-6.
33. Schmeiser HH, Janssen JWG, Lyons J, et al. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 1990;50: 5464-9.
34. Pourrat J, Montastruc JL, Lecombe IL, Cisterne JM, Rascol O, Dumazer P. Néphropathie associée à des herbes chinoises: 2 cas. Presse Med 1994;23:1669-70.
35. Peña JM, Borrás M, Ramos J, Montoliu J. Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Nephrol Dial Transplant 1996;11:1359-60.
36. Tanaka A, Shinkai S, Kasuno K, et al. Chinese herbs nephropathy in the Kansai area: a warning report. Jpn J Nephrol 1997;39:438-40. (In Japanese.)
37. Tanaka A, Nishida R, Sawai K, et al. Traditional remedy-induced Chinese herbs nephropathy showing rapid deterioration of renal function. Jpn J Nephrol 1997;39:794-7. (In Japanese.)
38. Lord GM, Tagore R, Cook T, Gower P, Pusey CD. Nephropathy caused by Chinese herbs in the UK. Lancet 1999;354:481-2.
39. Yang C-S, Lin C-H, Chang S-H, Hsu H-C. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000;35:313-8.